HCA
VKTX icon

Harbor Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Harbor Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$618K Sell
15,830
-10,179
-39% -$329K 0.04% 481
2026
Q1 		$846K Buy
26,009
+9,240
+55% +$297K 0.07% 357
2025
Q4 		$590K Buy
16,769
+600
+4% +$21.3K 0.05% 436
2025
Q3 		$425K Sell
16,169
-87,377
-84% -$2.61M 0.03% 522
2025
Q2 		$2.74M Sell
103,546
-11,643
-10% -$306K 0.12% 238
2025
Q1 		$2.78M Sell
115,189
-14,094
-11% -$445K 0.13% 231
2024
Q4 		$5.2M Sell
129,283
-9,969
-7% -$568K 0.23% 139
2024
Q3 		$8.82M Buy
139,252
+75,820
+120% +$4.45M 0.38% 70
2024
Q2 		$3.36M Buy
63,432
+55,068
+658% +$3.61M 0.26% 103
2024
Q1 		$686K Buy
+8,364
New +$372K 0.09% 302

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Harbor Capital Advisors's VKTX Position: Q2 2026 in Review

Harbor Capital Advisors reduced its Viking Therapeutics (VKTX) stake by 39% in Q2 2026, selling an estimated $329K and leaving 15,830 shares worth $618K. The position accounts for 0.04% of the portfolio, ranked #481.

Harbor Capital Advisors first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $8.82M in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Harbor Capital Advisors held 15,830 shares of Viking Therapeutics worth $618K as of Q2 2026.
  • Harbor Capital Advisors sold 10,179 Viking Therapeutics shares in Q2 2026, an estimated $329K.
  • Viking Therapeutics made up 0.04% of Harbor Capital Advisors's portfolio in Q2 2026, its #481 holding.
  • Harbor Capital Advisors first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Harbor Capital Advisors's Viking Therapeutics position peaked at $8.82M in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.